scPharmaceuticals Inc. (NASDAQ:SCPH) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET

Company Participants

PJ Kelleher - Investor Relations

John Tucker - Chief Executive Officer

Steve Parsons - Senior Vice President, Commercial

Rachael Nokes - Chief Financial Officer

Conference Call Participants

Glen Santangelo - Jefferies

Stacy Ku - TD Cowen

Doug Tsao - H.C. Wainwright

Naz Rahman - Maxim Group

Operator

Good day and welcome to the scPharmaceuticals Second Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to PJ Kelleher of LifeSci Advisors. Please go ahead.

PJ Kelleher

Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements on this conference call, other than historical facts, are forward looking statements within the meaning of the federal securities laws, including but not limited to statements regarding scPharmaceuticals, expected future financial results and management’s expectations and plans for the business and FUROSCIX.

The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project and other similar expressions are used typically to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance, but may involve and are subject to certain risks and uncertainties and other important factors that may affect scPharmaceuticals business, financial condition and other operating results. These include, but are not limited to, the risk factors and other qualifications contained in scPharmaceuticals annual report on Form 10-K, quarterly reports on Form 10-Q and other reports filed by the company with the SEC to which your attention is directed. Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. Any forward-looking statements made in this conference call, including responses to your questions are based on current expectations as of today and scPharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

It is now my pleasure to turn the call over to Mr. John Tucker, Chief Executive Officer of scPharmaceuticals. John?

John Tucker

Thank you, PJ and thanks to everyone listening to this afternoon’s call and webcast. This afternoon, I am pleased to provide an operational update before turning the call over to Steve Parsons, our Senior Vice President, Commercial for a more detailed update on the FUROSCIX launch and then Rachael Noakes, our Chief Financial Officer for a review of our financials. We will then open the call for your questions.